Glenn Noronha News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PYC Therapeutics Assembles Ophthalmology-Focused Clinical Advisory Board

PYC Therapeutics Assembles Ophthalmology-Focused Clinical Advisory Board
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesStanford universityUnited kingdomWestern australiaSan diegoUniversity collegeNew south walesCity ofSan franciscoMark pennesiSanta barbaraPhosphorodiamidate morpholino oligomerLeo vartorellaDeborah elson matthew deyoungGlenn noronhaKennethc swan

PYC Therapeutics Highlights Continued Progress of Ocular and CNS Pipeline Programs and U S Expansion in First Quarter Update

Share this article Share this article NEW YORK and PERTH, Australia, April 30, 2021 /PRNewswire/ PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced a first quarter update highlighting the progress of its development pipeline, growth of its U.S. operations and upcoming milestones. PYC has had an exciting quarter of progress against our Company objectives. We have achieved continued validation of our PPMO technology in our lead candidate VP-001 for retinitis pigmentosa type 11, further development of our ocular pipeline as well as PYC s first set of preclinical data from our CNS discovery efforts demonstrating superior delivery of RNA therapeutic throughout the brain and spinal cord. The potential of our pioneering PPMO technology is vast and we look forward to advancing this technology to provide solutions for patients with inherited ocular and ne

Western australiaMichael rosenblattPhosphorodiamidate morpholino oligomerKaggen ausmaSahm nasseriLeo vartorellaDeborah elson matthew deyoungGlenn noronhaDrug administrationExecutive officerAlan tribeOcular diseasesInvestigational new drugNervous systemChief development officerChief business officer

PYC Therapeutics Expands U S Executive Leadership Team with the Appointment of Glenn Noronha, PhD, as Chief Development Officer

Share this article Share this article PERTH, Australia and NEW YORK, Feb. 23, 2021 /PRNewswire/ PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced the appointment of Glenn Noronha, PhD, as Chief Development Officer. Dr. Noronha will oversee the Company s translational clinical development, regulatory, manufacturing and preclinical development activities as it advances its pipeline of multiple drug candidates which is initially focused on inherited ocular diseases. Dr. Noronha brings to PYC over 20 years of progressive leadership and research experience across both small and large biotechnology and pharmaceutical companies, with deep expertise in development of ophthalmology drug candidates, through his positions at BridgeBio Pharma, Clearside Biomedical and Alcon, formerly the ophthalmology subsidiary of Novartis. He has a proven track record of

United statesWestern australiaBio pharmaNavire pharmaLos angelesDeborah elson matthew deyoungSahm nasseriLeo vartorellaGlenn noronhaDevelopment officerUniversity of californiaDrug administrationJw theriac pharmaceuticalsChief developmentBridgebio pharmaClearside biomedical